首页> 美国卫生研究院文献>other >The Active Metabolite of Warfarin (3-Hydroxywarfarin) and Correlation with INR Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study
【2h】

The Active Metabolite of Warfarin (3-Hydroxywarfarin) and Correlation with INR Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study

机译:华法林的活性代谢产物(3-羟基华法林)及其与口服抗凝治疗患者INR华法林和药物每周剂量的相关性:药物遗传学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesWarfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy task. HPLC assessment of warfarin/enantiomers was suggested as a valid monitoring-tool along with INR, but definite results are still lacking. We evaluated possible correlations between INR, warfarin/3’-hydroxywarfarin, and drug weekly dosage aimed at searching novel alternatives to OAT monitoring. VKORC1/CYP2C9 pharmacogenetics investigation was performed to account for the known influence on warfarin homeostasis.
机译:目的华法林口服抗凝治疗(OAT)需要定期且频繁地通过INR进行药物调整。个体间的变异性,药物和饮食的干扰以及遗传因素(VKORC1和CYP2C9)使得维持/达到稳定的INR并非易事。推荐对华法林/对映异构体进行HPLC评估以及与INR一起作为有效的监测工具,但仍缺乏确切的结果。我们评估了INR,华法林/ 3'-羟基华法林与每周药物剂量之间的可能相关性,旨在寻找OAT监测的新替代方法。进行了VKORC1 / CYP2C9药物遗传学研究以解释对华法林体内稳态的已知影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号